Alpha 2.0
Login Register
» Authors » Alexandra Griessbach

Alexandra Griessbach

Explore the profile of Alexandra Griessbach including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 79
Followers 0
Related Specialties
General Medicine
Infectious Diseases
Public Health
Top 10 Co-Authors
Matthias Briel
Benjamin Speich
Alain Amstutz
Ala Taji Heravi
Frederique Chammartin
Christof M Schonenberger
Heiner C Bucher
Marcel P Stoeckle
Katharina Kusejko
Alexandra Trkola
Published In
J Clin Epidemiol
Open Forum Infect Dis
JAMA Netw Open
Stud Health Technol Inform
BMC Med Res Methodol
Affiliations
Soon will be listed here.
Recent Articles
1.
Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune function
Audige A, Amstutz A, Schuurmans M, Amico P, Braun D, Stoeckle M, et al.
PLoS One . 2025 Jan; 20(1):e0317965. PMID: 39854310
T-cell response plays an important role in SARS-CoV-2 immunogenicity. For people living with HIV (PWH) and solid organ transplant (SOT) recipients there is limited evidence on the reliability of commercially...
2.
Design and rationale for an empirical investigation of the resource use and costs of investigator-initiated randomized trials in Switzerland, the UK, and Germany
Griessbach A, Speich B, Dutilh G, Treweek S, Schwenkglenks M, Briel M
Trials . 2024 Oct; 25(1):662. PMID: 39375767
Background: Conducting high-quality randomized clinical trials (RCTs) is challenging, time consuming, and resource intense. Academic investigators usually depend on scarce financial resources; however, current literature lacks systematically collected empirical data...
3.
Resource use and costs of investigator-sponsored randomized clinical trials in Switzerland, Germany, and the United Kingdom: a metaresearch study
Griessbach A, Speich B, Amstutz A, Hausheer L, Covino M, Wnfried Ramirez H, et al.
J Clin Epidemiol . 2024 Sep; 176:111536. PMID: 39307405
Background And Objectives: Conducting high-quality randomized clinical trials (RCTs) is challenging and resource intensive. Funders and academic investigators depend on limited financial resources and, therefore, need empirical data for optimal...
4.
Characteristics, consent patterns, and challenges of randomized trials using the Trials within Cohorts (TwiCs) design - A scoping review
Amstutz A, Schonenberger C, Speich B, Griessbach A, Schwenke J, Glasstetter J, et al.
J Clin Epidemiol . 2024 Jul; 174:111469. PMID: 39032590
Objectives: Trials within Cohorts (TwiCs) is a pragmatic design approach that may overcome frequent challenges of traditional randomized trials such as slow recruitment, burdensome consent procedures, or limited external validity....
5.
Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study
Amstutz A, Chammartin F, Audige A, Eichenberger A, Braun D, Amico P, et al.
J Infect Dis . 2024 Jun; 230(4):e847-e859. PMID: 38848312
Background: Bivalent messenger RNA (mRNA) vaccines, designed to combat emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, incorporate ancestral strains and a new variant. Our study assessed the immune...
6.
Characteristics, Progression, and Output of Randomized Platform Trials: A Systematic Review
Griessbach A, Schonenberger C, Taji Heravi A, Gloy V, Agarwal A, Hallenberger T, et al.
JAMA Netw Open . 2024 Mar; 7(3):e243109. PMID: 38506807
Importance: Platform trials have become increasingly common, and evidence is needed to determine how this trial design is actually applied in current research practice. Objective: To determine the characteristics, progression,...
7.
Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2)
Griessbach A, Chammartin F, Abela I, Amico P, Stoeckle M, Eichenberger A, et al.
Open Forum Infect Dis . 2023 Nov; 10(11):ofad536. PMID: 38023564
Background: After basic immunization with 2 mRNA SARS-CoV-2 vaccine doses, only a small proportion of patients who are severely immunocompromised generate a sufficient antibody response. Hence, we assessed the additional...
8.
Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1
Chammartin F, Griessbach A, Kusejko K, Audige A, Epp S, Stoeckle M, et al.
AIDS . 2023 Oct; 38(2):217-222. PMID: 37830908
Objectives: This study aimed to investigate the association of demographic and clinical characteristics, including HIV-specific parameters with the antibody response to a third dose of a severe acute respiratory syndrome...
9.
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)
Griessbach A, Chammartin F, Abela I, Amico P, Stoeckle M, Eichenberger A, et al.
Open Forum Infect Dis . 2023 Apr; 10(4):ofad150. PMID: 37035486
Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared...
10.
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials
Amstutz A, Speich B, Mentre F, Rueegg C, Belhadi D, Assoumou L, et al.
Lancet Respir Med . 2023 Feb; 11(5):453-464. PMID: 36828006
Background: Interpretation of the evidence from randomised controlled trials (RCTs) of remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the benefits and harms of...